CA2304123A1 - Traitement contre les bacteries resistantes aux antibiotiques - Google Patents

Traitement contre les bacteries resistantes aux antibiotiques Download PDF

Info

Publication number
CA2304123A1
CA2304123A1 CA002304123A CA2304123A CA2304123A1 CA 2304123 A1 CA2304123 A1 CA 2304123A1 CA 002304123 A CA002304123 A CA 002304123A CA 2304123 A CA2304123 A CA 2304123A CA 2304123 A1 CA2304123 A1 CA 2304123A1
Authority
CA
Canada
Prior art keywords
bacteria
mrsa
isolated
bacteriophage
bacteriophages
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002304123A
Other languages
English (en)
Inventor
Max Kelly
Allison Mcgeer
Barbara M. Willey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mt Sinai Hospital
Original Assignee
Mt Sinai Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mt Sinai Hospital filed Critical Mt Sinai Hospital
Priority to CA002304123A priority Critical patent/CA2304123A1/fr
Publication of CA2304123A1 publication Critical patent/CA2304123A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002304123A 2000-04-19 2000-04-19 Traitement contre les bacteries resistantes aux antibiotiques Abandoned CA2304123A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002304123A CA2304123A1 (fr) 2000-04-19 2000-04-19 Traitement contre les bacteries resistantes aux antibiotiques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002304123A CA2304123A1 (fr) 2000-04-19 2000-04-19 Traitement contre les bacteries resistantes aux antibiotiques

Publications (1)

Publication Number Publication Date
CA2304123A1 true CA2304123A1 (fr) 2001-10-19

Family

ID=4165796

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002304123A Abandoned CA2304123A1 (fr) 2000-04-19 2000-04-19 Traitement contre les bacteries resistantes aux antibiotiques

Country Status (1)

Country Link
CA (1) CA2304123A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008097115A1 (fr) * 2007-02-09 2008-08-14 Instytut Immunologii I Terapii Doswiadczalnej Pan Bactériophage purifié, sa préparation et son application
WO2009087356A1 (fr) * 2008-01-04 2009-07-16 Novolytics Limited Phage de changement de gamme d'hôtes
CN109666654A (zh) * 2015-06-09 2019-04-23 菲吉乐科(南京)生物科技有限公司 新的噬菌体、其组合物以及它们的制备方法和应用
CN115103665A (zh) * 2020-01-14 2022-09-23 Pha科技有限公司 噬菌体制剂和噬菌体应用装置
CN120442561A (zh) * 2025-04-19 2025-08-08 青岛润达生物科技有限公司 一种跨种裂解噬菌体rdp-ec-20146及其应用

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008097115A1 (fr) * 2007-02-09 2008-08-14 Instytut Immunologii I Terapii Doswiadczalnej Pan Bactériophage purifié, sa préparation et son application
US9255251B2 (en) 2007-02-09 2016-02-09 Instytut Immunologii I Terapii Doswiadczalnej Pan Purified bacteriophage, its preparation and application
WO2009087356A1 (fr) * 2008-01-04 2009-07-16 Novolytics Limited Phage de changement de gamme d'hôtes
CN109666654A (zh) * 2015-06-09 2019-04-23 菲吉乐科(南京)生物科技有限公司 新的噬菌体、其组合物以及它们的制备方法和应用
CN109666654B (zh) * 2015-06-09 2022-05-31 菲吉乐科(南京)生物科技有限公司 新的噬菌体、其组合物以及它们的制备方法和应用
CN115103665A (zh) * 2020-01-14 2022-09-23 Pha科技有限公司 噬菌体制剂和噬菌体应用装置
CN120442561A (zh) * 2025-04-19 2025-08-08 青岛润达生物科技有限公司 一种跨种裂解噬菌体rdp-ec-20146及其应用

Similar Documents

Publication Publication Date Title
US20020001590A1 (en) Antibacterial therapy for multi-drug resistant bacteria
US11957724B2 (en) Phage therapy of E coli infections
US7758856B2 (en) Bacteriophage for the treatment of bacterial biofilms
Abedon Bacteriophage clinical use as antibacterial “drugs”: utility and precedent
US12280080B2 (en) Antibacterial composition and uses thereof
ES2857199T3 (es) Terapia con fagos de infecciones de Pseudomonas
JP7449967B2 (ja) 療法バクテリオファージ組成物
JP2021508740A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染症を処置するための治療的バクテリオファージ組成物
US11253557B2 (en) Therapeutic bacteriophage compositions
US20100291041A1 (en) Bacteriophage preparation and use
US20040146490A1 (en) Antibacterial therapy for multi-drug resistant bacteria
CA2304123A1 (fr) Traitement contre les bacteries resistantes aux antibiotiques
Rezaei Bacteriophages for the treatment of resistant bacterial infectious diseases
Ali et al. Extraction, purification and therapeutic use of bacteriophage endolysin against multi-drug resistant Staphylococcus aureus: In vivo and in vitro study.
Lokesh et al. Phage as medicine for bacterial diseases
Ghareeb Bacteriophages effects on antibiotic sensitivity of Staphylococcus aureus ﺔﯾﻮﯿﺤﻟا تادﺎﻀﻣ هﺎﺠﺗ ﺔﯿﺒھﺬﻟا ﺔﯾدﻮﻘﻨﻌﻟا تارﻮﻜﻤﻟا ﺎﯾﺮﺘﻜﺑ ﺔﯿﺳﺎﺴﺣ ﻰﻠﻋ تﺎﯿﺛﺎﻌﻟا ﺮﯿﺛﺄﺗ
HK1227713B (en) Phage therapy of e coli infections
HK1227713A1 (en) Phage therapy of e coli infections

Legal Events

Date Code Title Description
FZDE Dead